Items tagged with Scientific research

Scientists develop new drug treatment for TB (post)

Scientists at The University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals.

Why some TB bacteria prove deadly (post)

A new study has found that the same mutation that gives tuberculosis bacteria drug resistance also elicits a different -- and potentially weaker -- immune response.

A naturally occurring antibiotic active against drug-resistant TB (post)

A naturally occurring antibiotic called kanglemycin A is effective against Mycobacterium tuberculosis, the bacteria that cause tuberculosis, even in drug-resistant strains, according to an international team of researchers who used chemistry, molecular biology, microbiology, and X-ray crystallography to show how the compound maintains its activity. A paper describing the research appears September 20, 2018 in the journal Molecular Cell.

TB Alliance and Liverpool School of Tropical Medicine collaborate to develop new TB therapies (post)

LIVERPOOL (September 19, 2018) – The Liverpool School of Tropical Medicine (LSTM) and TB Alliance are collaborating to investigate novel combination drug therapies that could help the fight against multidrug-resistant tuberculosis (MDR-TB), following an award of £1 million from the Medical Research Council.

NIH releases strategic plan to address TB research (post)

Tuberculosis (TB) is the leading infectious cause of death worldwide, killing roughly 1.6 million people in 2017. In the past 200 years, TB claimed the lives of more than 1 billion people — more deaths than from malaria, influenza, smallpox, HIV/AIDS, cholera and plague combined.

Latest scientific advances in the field of TB (post)

TB Alliance joins Innovative Medicines Initiative to accelerate development of new TB cures (post)

[October 24, 2018, NEW YORK] - TB Alliance has joined the Innovative Medicines Initiative (IMI) as an Associated Partner on programs focused on antimicrobial resistance and innovation in clinical trials. IMI is a public-private partnership between the European Union and the European pharmaceutical industry that facilitates the development of medicines, especially in areas of unmet medical need including tuberculosis (TB). 

Searching in soil, scientists find a new way to combat TB (post)

For decades, doctors have been using antibiotics to fight tuberculosis (TB). And consistently, the microbe responsible for the disease, Mycobacterium tuberculosis, has been fighting back. When confronted with current drugs, such as the antibiotic rifamycin, the bacterium often mutates in ways that make it resistant to the treatment.

Can an exhausted lung cell of a smoker fight bacterial infection? (post)

Researchers at Trinity College Dublin have discovered how lung cell exhaustion affects a patient’s ability to fight diseases.

Lymph nodes are niches for prolonged tuberculosis infection (post)

Lymph nodes can contain large numbers of tuberculosis-causing bacteria and serve as long-term reservoirs of bacterial persistence, according to a study published November 1 in the open-access journal PLOS Pathogens by JoAnne Flynn of the University of Pittsburgh School of Medicine, and colleagues. As niches for persistent infection, these organs are likely to play a larger role in tuberculosis than previously appreciated.